ArticleJournal of blood medicine2026
Detection of IDH1, IDH2, and NPM1 Mutations in Acute Myeloid Leukemia by High-Resolution Melting Analysis in Comparison with Direct Sequencing and MRD Detection.
Article in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute Myeloid Leukemia (AML) is a heterogeneous type of acute leukemia. Genetic mutations are the most important prognostic factors in AML. Mutations that affect isocitrate dehydrogenase 1 and 2 (IDH1 and 2) genes are associated with poor prognosis, but the nucleophosmin 1 (NPM1) mutation is favorable. In this study, we investigated the efficiency of the High-Resolution Melting (HRM) method for the detection of NPM1, IDH1, and IDH2 mutations, and used it for minimal residual disease detection. Methods: Formalin-fixed, paraffin-embedded (FFPE) marrow biopsies of 78 patients with AML were analyzed. Mutation detection was performed using the HRM method and the results were compared with those obtained by direct sequencing. The melting temperatures (Tm) were analyzed using the blast cell percentage. Results: NPM1, IDHs mutations were detected in 28 (35.8%) and 21 (26.9%) samples, respectively. Among all IDH mutations, 13 (16.6%) and eight (10.2%) samples were harboring the IDH-1 and -2 gene mutations, respectively. Based on the HRM results, samples with higher blast cells had a minimal difference in Tm compared to samples with higher blast cells. Conclusion: Our study is generally distinguished from previous studies based on the desirable characteristics of the HRM method. Regarding mutation detection in low amounts of extracted DNA, the relationship between Tm and the blast percentage is an advantageous characteristic of the HRM method. As shown in a previous study, the use of NPM1 and IDHs for the detection of Minimal Residual Disease (MRD) by HRM is a sensitive method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.